Conditions & Recovery · ScienceDaily Cancer · July 11, 2026

Common blood pressure drug could make cancer therapy far more powerful

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer drug olaparib, potentially expanding its benefits beyond patients with BRCA-related tumors. The combination is already being tested in human clinical trials after showing strong immune-boosting and anticancer effects in preclinical studies.

Originally published by ScienceDaily Cancer. We curate and add context; they did the reporting.

Read the full story at ScienceDaily Cancer ↗

Related learning

Biotech Firm Claims Some Credit for Groundbreaking Virus Research Biotech Firm Claims Some Credit for Groundbreaking Virus Research James P. Allison, Ph.D., bangs gong after completing proton therapy treatment Combination therapy helps plasmacytoid bladder cancer survivor